



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

DAVID L. PARKER  
PARTNER  
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

April 17, 2006

## CERTIFICATE OF MAILING 37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 17, 2006

Date

David L. Parker

## MS AMENDMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

RE: *U.S. Patent Application No. 08/844,731 entitled "METHODS OF TREATING AUTOIMMUNE DISEASES USING TYPE ONE INTERFERONS" – Staley A. Brod*  
*Our reference: CLFR:114US*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references C1-C4.

The Commissioner is authorized to deduct the fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/CLFR:114US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker  
Reg. No. 32,165

DLP/mpb

08844731

05/01/2006 WARDELR1 00000066 501212  
03 FC:1806 180.00 DA

Form PTO-1449 (modified)

APR 28 2006

Atty. Docket No.  
CLFR:114USSerial No.  
08/844,731**List of Patents and Publications from Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
Staley A. BrodFiling Date:  
April 21, 1997Group:  
1761**U.S. Patent Documents***See Page 1***Foreign Patent Documents***See Page 1***Other Art***See Page 1***U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C1	Brod, "Ingested IFN-alpha: Results of a pilot study in relapsing-remitting MS," <i>Neurology</i> , 57:845-852, 2001.
	C2	Cummins <i>et al.</i> , "Oral use of human alpha interferon in cats," <i>J. Biol. Response Mod.</i> 7:513-423. 1988. (abstract)
	C3	Koren and Fleischmann, "Orally administered interferons suppress bone marrow function," <i>P.S.E.B.M.</i> , 204:155-164, 1993.
	C4	Soos <i>et al.</i> , "Cutting Edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate," <i>J. Immunol.</i> , 169: 2231-2235, 2002.

25646123.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.